These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38066554)

  • 1. Antitumor effect of a small-molecule inhibitor of KRAS
    Vázquez-Borrego MC; Granados-Rodríguez M; Bura FI; Martínez-López A; Rufián-Andújar B; Valenzuela-Molina F; Rodríguez-Ortiz L; Haro-Yuste S; Moreno-Serrano A; Ortega-Salas R; Pineda-Reyes R; Michán C; Alhama J; Romero-Ruiz A; Arjona-Sánchez Á
    Exp Hematol Oncol; 2023 Dec; 12(1):102. PubMed ID: 38066554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
    Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
    Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
    Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
    Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Kras
    Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Sugimoto H; Arian KA; Ying H; Barekatain Y; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
    bioRxiv; 2023 Feb; ():. PubMed ID: 36824971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
    Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
    J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways and mechanism of MRTX1133 binding to KRAS G12D elucidated by molecular dynamics simulations and Markov state models.
    Tu G; Gong Y; Yao X; Liu Q; Xue W; Zhang R
    Int J Biol Macromol; 2024 Aug; 274(Pt 2):133374. PubMed ID: 38925182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor efficacy of a potent and selective non-covalent KRAS
    Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
    Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
    Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
    J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
    Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
    Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition mechanism of MRTX1133 on KRAS
    Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
    J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
    Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
    Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
    Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
    J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of Pseudomyxoma Peritonei of an unexpected origin.
    Csanyi-Bastien M; Blanchard F; Lamy A; Sabourin JC
    Diagn Pathol; 2021 Dec; 16(1):119. PubMed ID: 34930348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
    Bannoura SF; Khan HY; Azmi AS
    Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
    Khan S; Budamagunta V; Zhou D
    Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS
    Ji X; Li Y; Kong X; Chen D; Lu J
    ACS Omega; 2023 Feb; 8(7):7211-7221. PubMed ID: 36844555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report.
    Shelekhova KV; Zhuravlev AS; Krylova DD; Konstantinov AS; Shtan LV; Kheinshtein VA
    Int J Surg Pathol; 2017 Sep; 25(6):563-566. PubMed ID: 28449606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
    Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
    Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma.
    Taguchi A; Rokutan H; Oda K; Tanikawa M; Tanimoto S; Sone K; Mori M; Tsuruga T; Kohsaka S; Tatsuno K; Shinozaki-Ushiku A; Miyagawa K; Mano H; Aburatani H; Ushiku T; Osuga Y
    BMC Med Genomics; 2022 Mar; 15(1):51. PubMed ID: 35255903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.